StockNews.com lowered shares of DexCom (NASDAQ:DXCM – Free Report) from a buy rating to a hold rating in a research report report published on Saturday. A number of other analysts have also weighed in ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

In what makes Abbott Laboratories a serious competitor is the much lower price one has to pay for FreeStyle Libre - in comparison to Dexcom's G6 (or G7) and also in comparison to Medtronic's Guardian.

Equities researchers at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for DexCom in a research ...

Jefferies analyst Matthew Taylor maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Medicare's decision to reimburse for the G6 and G7 is a favorable ... Meaningful innovation should allow Dexcom to compete on other dimensions than price. Unlike most diagnostics where it is ...

Its innovative devices like the G6 and ... pricing and cost pressures possibly driven by competition, as well as innovations in related medical fields. Despite these challenges, DexCom maintained ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of ... DexCom G5 Mobil, DexCom G6, and DexCom Share.

The introduction of sensors like G6 and G7 in international markets also fueled revenue growth. Dexcom anticipates strong ... tickers "Most Likely for Early Price Pops." Since 1988, the full ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against the other IoT stocks. The Internet of Things (IoT) is a vast network connecting physical objects to ...